In Cyprus, legally available drugs include EIDD-1931 (active break-down product of anti-viral Molnupiravir), and GS-441524 (active break-down product of anti-viral Remdesivir). These drugs have not been through rigorous licensing, but studies are available, with most published for GS-441524, which apparently cures ~85% of ‘traditional’ cases. Molnupiravir appears as effective as GS-441524, but little data have yet been published for EIDD-1931.In this study, researchers will compare EIDD-1931 and GS-441524in cats with ‘traditional’ FIP and FCoV-23.
Study ID
D25FE-711
Study Status
Active
Start Date
11/01/2024
Grant amount awarded
$95,273
Grant recipient
University of Edinburgh
Study country
United Kingdom
Investigator
Danielle Gunn-Moore